Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Clinical trial NCT02855203 · COMPLETED
Trial details
- NCT number
- NCT02855203
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-20
- Primary completion
- 2020-05-22
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.